Key Abstracts from ASCO 2021 in NSCLC

Mark A. Socinski, MD

Key Abstracts from ASCO 2021 in NSCLC

Conference Correspondent - AACR & ASCO 2021 - Midyear Review

Medical Oncologist, Thoracic Cancer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL

Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC.

Maria E. Arcila, MD, Mark A. Socinski, MD, Lauren Welch, MSN, NP-C, AOCNP

Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine published on June 27, 2022

Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma

Mark A. Socinski, MD

Conference Correspondent published on December 14, 2021 in Dual IO 2021 Year in Review

Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC

Mark A. Socinski, MD

Conference Correspondent published on December 14, 2021 in Dual IO 2021 Year in Review

2021 Midyear Review: Non–Small-Cell Lung Cancer

Conference Correspondent published on June 20, 2021 in AACR & ASCO 2021 - Midyear Review

Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement